A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC

Conditions:   Squamous Cell Carcinoma of the Oropharynx;   HPV16 Positive
Interventions:   Biological: ISA101b;   Drug: Cemiplimab;   Other: Placebo
Sponsors:   ISA Pharmaceuticals;   Regeneron Pharmaceuticals
Not yet recruiting

https://ift.tt/2x6QAu7